Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | KMV002 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on KMV002, a putative combination of SN3001C and a CpG ODN adjuvant (Oct 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| KMV002 | KMV-002|KMV 002|IPT-PAP | Limited information is currently available on KMV002, a putative combination of SN3001C and a CpG ODN adjuvant (Oct 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07866300 | Phase I | KMV002 | A Study of KMV002 in Patients With mAPMR Prostate Cancer | Not yet recruiting | AUS | 0 |